KLK3 and prostate carcinoma: In patients with advanced prostate cancer, CCS1477 modulated the levels of plasma kallikrein-related peptidase 3 (KLK3), a marker associated with prostate-specific antigen (PSA) [92] and regulated key prostate cancer therapeutic targets [91].